•The ESMO guidelines state that all patients with high-grade ovarian cancer should be tested for BRCA1 and BRCA2 mutations (germline/somatic) at diagnosis (Colombo and Ledermann, 2021). The gene discussed is BRCA2; the disease is ovarian carcinoma.